Kornimate/medical-research-clean huggingface dataset:
role of the neonatal fc receptor for igg in the pathophysiology of lupus

Conditions: Lupus Erythematosus, Systemic

Summary: this study evaluates the expression of the neonatal fc receptor (fcrn) in white blood cells and antigen-presenting cells (apc) in active lupus patients compared to inactive lupus patients and control to investigate if it's upregulated or not.

fcrn is an intracellular receptor which binds the fc of immunoglobulins g (igg) and albumin which induce an upgraded half-life of this two proteins. it's extended role involve the regulation of immune complexes and anti-tumoral immunity, some studies showing a direct correlation between it's expression and the tumor surface and prognosis. recently a role in the upregulation of humoral response with a increase of the antibodies's diversity and a more efficient priming of lymphocyte b have been evocated. the lupus erythematosus is an auto-immune disease mediated by igg and immune complexes characterized by a high diversity of autoantibodies and a large dysregulation of the immune system in all it's components. in this study, by analogy with the founding in anti-tumoral immunity, the investigators hypothesised that in an active lupus disease the expression of fcrn is upregulated in the white blood cells and in apc. this is followed by an extended half life of igg autoantibodies and immune complexes inducing direct damages by their deposit in tissues and indirectly by upregulating the humoral response, leading to anormal production of a large panel of autoantibodies.

Eligibility criteria:
inclusion criteria: * lupus erythematosus newly diagnosed or active * inactive lupus erythematosus * needing a blood sample for diagnosis or follow up * signed informed consent exclusion criteria: * other auto immune disease * pregnant or brest feeding * legal protection or protected adults
lutein, zeaxathin, and fish oil supplementation

Conditions: Cognitive Performance; Age-Related Macular Degeneration; Bone Loss

Summary: the goal of this clinical trial is to learn the impact of lutein, zeaxanthin, and fish oil (lzf) supplementation in healthy adults. the main question it aims to answer is: will supplementation with lzf improve macular pigment optical density (mpod), cognitive performance and bone mass compared to controls after six months? subjects with an mpod \<.43 will significantly improve mpod after 6-months of lzf supplementation. consuming a lzfo supplement for 6-months will improve visual cognitive performance. consuming a lzfo supplement for 6-months will improve bone density. participants will be asked to take either a lzf supplement or placebo daily for 6 months.

macular degeneration, cognitive decline, and osteoporosis often occur with aging. lutein, zeaxanthin, and fish oil (lzf) have been shown to have improvements in these areas. this 6-month double-blind randomized controlled trial will study the impact of lzf on cognitive performance, macular pigment optical density (mpod), and bone health in healthy adults ages 18-45 with a mpod \<.43. we seek to create a precision nutrition model reducing macular degeneration, cognition, and bone health that includes non-invasive screening for high-risk carotenoid deficiencies (mpod, dietary intake) and individual response to lzf supplementation. healthy adults ages 18-45 years with mpod \<.43 will be randomly assigned to take a lzf supplement with 7 mg lutein, 14 mg zeaxanthin, and 245 mg fish oil or a placebo daily for six months. they will have baseline and ending measures of fasting blood draw, mpod, bone health using a dxa, and visual cognitive performance using neurotracker software.

Eligibility criteria:
inclusion criteria: * \<.43 mpod, a self-reported best-corrected vision of 20/40 or better in each eye, a bmi range of 18.5-30, and meets the inclusion criteria on the preliminary participant questionnaire. exclusion criteria: * allergic to lutein, zeaxanthin, or fish oil, taking supplements with \>6 mg lutein and/or \>2 mg zeaxanthin for more than two months before study starts, mpod between \>.43, self-reported condition of vertigo, diabetic retinopathy, retinitis pigmentosa, optic neuropathy, retinal vascular occlusions, strabismus, autoimmune disorders related to visual health, currently pregnant or trying to become pregnant, history of concussion, vegan (due to gelatin in the placebo), and/or taking neuroactive medications, such as ritalin, adderall, antidepressants, etc.

Keywords: lutein zeaxanthin fish oil supplement macular pigment macular pigment optical density cognition age-related macular degeneration cognitive performance
multi-site near infrared spectroscopy (nirs) monitoring of children during exercise

Conditions: Congenital Heart Disease

Summary: near infrared spectroscopy (nirs) monitoring has proven beneficial in increasing safety and improving patient care during pediatric cardiac surgery and during pediatric intensive care unit (picu) stays. nirs estimates the amount of oxygen in tissues by comparing the tissue's absorption of two wavelengths of light corresponding to hemoglobin carrying oxygen and hemoglobin without oxygen. during cardiac surgery, multi-site nirs monitoring is used to determine the heart's output by comparing the amount of oxygen available to discrete regions of the body nourished by different parts of the circulatory system. nirs leads placed on the forehead detect oxygen available to the brain (cerebral), while leads placed over the kidney reflect oxygen available to the internal organs (somatic). nirs monitoring has been used for studying muscle oxygen usage during exercise in normal and disease states. cerebral oxygenation at peak exercise at has been studied with nirs monitoring. the use of multi-site nirs monitoring during exercise stress testing for studying cardiac output through the patterning of somatic and cerebral oxygenation in combination with exercise stress test data has not been researched. we hypothesize that addition of multi-site nirs monitoring to the standard data collection already achieved during exercise testing, will enable calculation of anaerobic threshold and cardiac output prediction. this will assist in determining appropriate timing for surgical intervention, predicting the post operative course and testing response to medication.


Eligibility criteria:
inclusion criteria: * children and adolescents from age 6 to 20 undergoing exercise stress testing on treadmill exclusion criteria: * children and adolescents unable to exercise or unable to follow directions or unable to understand english.

Keywords: nirs cardiac output anaerobic threshold exercise stress congenital heart defect
role of vascular endothelial growth factor (vegf) in acute lung injury/adult respiratory distress syndrome (ards)

Conditions: Respiratory Distress Syndrome, Adult

Summary: understanding the role vegf plays in ards consequently provides an ideal opportunity to discover new therapies for ards.

in previous lab experiments, we observed evidence of pulmonary edema following alveolar epithelial overexpression of vegf, suggesting a potential role for vegf in ards. in addition, we found that preventing vegf from reaching its target receptor(s) by overexpressing a soluble form of a vegf receptor protein prevents edema formation. these observations heighten the plausibility of vegf playing an important role in the development of increased pulmonary capillary permeability during acute lung injury. understanding this role vegf plays in ards consequently provides an ideal opportunity to discover new therapies for ards.

Eligibility criteria:
inclusion criteria: 1. patients that meet the american-european consensus conference criteria for ards \[(1) widespread pulmonary infiltrates; (2) pulmonary capillary wedge pressure 18 mmhg; (3) paoz/fio; ratio 200; (4) compatible history\], or acute lung injury \[same as ards, but paoz/fioz ratio 300\], or are at increased risk for developing acute lung injury because of sepsis, pancreatitis, trauma, acid aspiration, radiation or chemotherapy-induced lung toxicity, and near drowning. pulmonary edema is divided into two broad categories: hydrostatic or cardiogenic and increased-permeability or noncardiogenic edema12. since ards is noncardiogenic in origin, patients with pulmonary edema due to congestive heart failure will serve as a control group. 2. inpatients that are endotracheally intubated. 3. patients that are able to provide informed consent or informed consent is granted by a family member or legal health care proxy. 4. males or females that are 18 years or older. exclusion criteria: - individuals who are too hypoxemic for bronchoscopy to be performed safely. patients requiring v\\0z \> 0.7 and/or peep 15 will be excluded. 2. if the patient will be unable to tolerate bronchoscopy because of severe acidosis, tension pneumothorax, active bronchospasm, hemodynamically significant cardiac arrhythmia, or intractable shock as defined as the inability to maintain a mean arterial pressure 60 mmhg or severe uncorrectable bleeding diathesis (tendency) or as otherwise determined by the pulmonary physician. 3. females who are pregnant will not be accepted into the study. 4. patients with recent (48 hours) acute myocardial infraction will not be accepted into the study. 5. patients with a history of adverse reactions to lidocaine will be not be accepted into the study. 6. patients who lack capacity to give informed consent due to acute panic attack, "intensive care unit" psychosis or other psychologic dysfunction.

Keywords: respiratory distress syndrome, adult
non-inferiority study of the effect of non-cooling blanket on body temperature in patients with heat stroke

Conditions: Heat Stroke

Summary: the goal of this clinical trial is to test the cooling effect of cooling blanket in patients with heat stroke. the main questions it aims to answer are: * the cooling rate of cooling blanket in patients with heat stroke * the relationship between cooling blanket and outcomes in patients with heat stroke participants will accept the cooling blanket or non-cooling blanket according to the randomization group. researchers will compare cooling rate and outcomes to see if the cooling blanket can accelerate the cooling speed and improve the prognosis of patients in heat stroke.


Eligibility criteria:
inclusion criteria: * ≥ 18 years old * diagnosed as heat stroke * informed consent of patients or family members exclusion criteria: * need immediate cardiopulmonary resuscitation * body temperature \&lt;39.5℃ on admission * with the underlying disease of severe organ damage * pregnant women

Keywords: heat stroke, cooling blanket, cooling rate, outcomes
indapamide versus hydrochlorothiazide in elderly hypertensive patients with renal insufficiency

Conditions: Hypertension; Renal Insufficiency

Summary: the purpose of this study is to evaluate the effects of indapamide sr 1.5 mg on renal function, endothelial function, blood pressure variability by comparison with hydrochlorothiazide 25 mg, in patients with mild to moderate renal insufficiency and hypertension.


Eligibility criteria:
inclusion criteria: * creatinine clearance 30 to 90 ml/min/1.73 m2, with variations of less than 20 percent in the 2 weeks before the screening evaluation. * diagnosed hypertension according to guidelines or having taken anti-hypertension drugs. * aged between 65 and 85 years. * willingness to provide written, informed consent. * ability to adhere to study protocol. exclusion criteria: * secondary hypertension. * diabetes mellitus. * atrial flutter/atrial fibrillation. * symptoms of congestive heart failure (nyha iii-iv) or there is evidence that left ventricular ef \< 40%. * recent (\< 6 months) myocardial infarction or cerebrovascular ischemic symptoms. * recent (\< 3 months) or planned coronary revascularization: pci (percutaneous coronary intervention)/cabg (coronary artery by-pass graft). * severe valvular heart disease. * history of hypersensitivity to indapamide, thiazides or to any of the components of the products. * any current condition or other disease known to interfere significantly with the absorption, distribution, metabolism or excretion of study drugs. * participation to another investigational study in the last 3 months.

Keywords: hypertension renal insufficiency indapamide hydrochlorothiazide
effects of time-restricted eating and aerobic exercise training in women with overweight and obesity

Conditions: Time Restricted Eating; Obesity; Intermittent Fasting; Overweight and Obesity; Time Restricted Feeding

Summary: time-restricted eating (tre) is a dietary approach that aims to increase fasting time and decrease the eating window. promising tre effects on weight loss and improvements in some cardiometabolic risk factors have been reported in studies in animals and humans. however, the impacts of tre combined with aerobic exercise training in individuals with overweight and obesity have been insufficiently investigated. additionally, aerobic training performed in a fasted state appears to promote physiological adaptations that may improve the metabolic health in individuals with overweight and obesity. the present study investigates the effects of 8 weeks of tre associated with aerobic training in a fasted state versus a fed state on body composition and cardiometabolic parameters in women with overweight and grade 1 obesity.


Eligibility criteria:
inclusion criteria: * female; * body mass index (bmi) between 25 and 34.9 kg/m²; * age between 20 and 40 years; * not engaged in any structured exercise program; * weight stable for \~3 months before the beginning of the study; * able to give written informed consent. exclusion criteria: * current smoker; * habitual drinkers (\>1 serving/day) of alcoholic beverages; * cardiometabolic diseases (dyslipidemia, diabetes, hypertension, etc); * current treatment with medication or supplements which significantly affect the main studied variables; * bariatric surgery; * night-shift workers; * strict vegetarian/vegan; * pregnancy, planned pregnancy (within the study period), lactating; * postmenopausal women; * self-reported menstrual cycle irregularities; * habitual fasting window \>16 hours; * concomitant participation in other studies.
dynamic imaging of the subtalar instability

Conditions: Subtalar Arthritis; Subtalar Instability

Summary: the purpose of this study is to describe normal dynamic computed tomography anatomy of hind foot in inversion/eversion movement, and to define diagnostic criteria for subtalar instability.

dynamic ct (aquilion one toshiba) of the ankle during inversion and eversion movement will be performed in patients from three groups: healthy volunteers, patients with subtalar arthritis, and patients with suspicion of subtalar instability.

Eligibility criteria:
inclusion criteria: * group instability: suspicion of subtalar instability * group arhtritis: subtalar stiffness * group healthy volunteers: healthy volunteers * conscious and cooperating * written consent obtained after oral and written clear and intelligible information * no pregnancy exclusion criteria: * pregnancy * unable to understand information about this study * unable to understand the movement of inversion / eversion of ankle * absence of affiliation to social security

Keywords: subtalar arthritis subtalar instability
uro-902 in female subjects with overactive bladder and urge urinary incontinence

Conditions: Overactive Bladder With Urge Urinary Incontinence

Summary: this study will evaluate the efficacy, safety, and tolerability of a single dose of uro-902 24 milligrams (mg) and 48 mg (administered via intradetrusor injection), compared with placebo, in participants with overactive bladder (oab) and urge urinary incontinence (uui) up to 48 weeks post-dose.


Eligibility criteria:
inclusion criteria: * participant has symptoms of overactive bladder (oab) (frequency and urgency) with urge urinary incontinence (uui) for a period of at least 6 months prior to screening. * participant experiences ≥ 1 episode of uui per day. * participant has not been adequately managed with ≥ 1 oral or transdermal pharmacologic therapies for the treatment of their oab symptoms. exclusion criteria: * participant has symptoms of oab due to any known neurological reason (e.g., spinal cord injury, multiple sclerosis, cerebrovascular accident, alzheimer's disease, parkinson's disease, etc). * participant has a predominance of stress incontinence in the opinion of the investigator, determined by participant history. * participant currently uses or plans to use medications or therapies to treat symptoms of oab, including nocturia. * participants who have previously been treated with onabotulinumtoxina for urological indications within 12 months of starting the screening bladder diary, or any other toxin for urological indications, regardless of when treated (participants treated with onabotulinumtoxina or other toxins for non-urological indications are eligible, regardless of when treated)

Keywords: uro-902 hmaxi-k pvax/hslo overactive bladder urge urinary incontinence
a study of shr-9803 for injection in patients with advanced solid tumors

Conditions: Advanced Solid Tumors

Summary: this is an open label, multi-center, multiple doses phase i/ii study to evaluate the safety, tolerability ,pharmacokinetics and efficacy of shr-9803 for injection in subjects with advanced solid tumors.


Eligibility criteria:
inclusion criteria: 1. voluntary participation and written informed consent. 2. 18-75 years old, no gender limitation. 3. eastern cooperative oncology group (ecog) score: 0-1 4. with a life expectancy ≥ 3 months. 5. pathologically diagnosed advanced solid tumor. 6. at least one measurable lesion according to recist v1.1. 7. adequate bone marrow reserve and organ function. 8. contraception is required during clinical trials, and pregnancy tests must be negative for women of childbearing age within 7 days before the first dose. exclusion criteria: 1. have untreated central nervous system metastasis; or have meningeal metastasis or spinal cord compression; 2. uncontrolled clinically symptomatic pleural effusion, pericardial effusion, or ascites; 3. previous or co-existing malignancies； 4. severe bone damage caused by bone metastasis， including uncontrolled tumor-related pain; 5. have active or prior documented autoimmune disease; 6. have used corticosteroids (\> 10 mg/day of prednisone or equivalent) or other immunosuppressive agents for systemic treatment within 2 weeks; 7. with poorly controlled or severe cardiovascular disease; 8. a history of interstitial pneumonia/non-infectious pneumonia; 9. severe infection 1 month before the first dose; 10. active hepatitis b or hepatitis c, or with a history of immunodeficiency; 11. with a history of inflammatory bowel disease, or those who have experienced intestinal obstruction or gastrointestinal perforation within 3 months prior to the first dose; 12. have received more than 30 gy of pulmonary radiation therapy within 6 months prior to the first dose; have received major surgery，systemic chemotherapy, endocrine therapy, monoclonal antibody therapy, macromolecular targeted therapy or other investigational products within 4 weeks; or palliative radiotherapy within 2 weeks; or oral small-molecule targeted drugs within five half-lives; 13. have not recovered from the toxicities and/or complications of previous interventions to nci-ctcae grade ≤ 1; 14. received live-attenuated vaccines within 4 weeks prior to the first dose. 15. known to have had an allergic reaction to other monoclonal antibodies.
the effect of daily dietary intake of dried juice concentrates of fruit, vegetables and berries upon outcomes of chronic periodontitis

Conditions: Periodontitis

Summary: the objective of this study is to determine whether enhanced micronutrient intake in the form of fruit, vegetable and berry juice powder (fvb) concentrate, improves clinical outcomes in chronic periodontitis patients prior to standard non-surgical treatment.

the objective of this study is to determine whether enhanced micronutrient intake in the form of fruit, vegetable and berry juice powder (fvb) concentrate, improves clinical outcomes in chronic periodontitis patients prior to non-surgical treatment. in addition, the effects of supplementation prior to and following standard non-surgical management will be assessed, relative to a placebo supplemented group. the investigators hypothesize that 3-months of nutritional support using this fvb will result in additional reductions in marginal gingival inflammation (bleeding) and additional reductions in probing pocket depth (mean \& cumulative), over and above any placebo-related or behavioral effect. in addition, the investigators hypothesize that 3-months of nutritional support prior to a standard non-surgical therapy in conjunction with a continuation of the nutritional support for 3 months will result in further additional reductions in marginal gingival inflammation and probing pocket depth, over and above any placebo-related or behavioral effect following standard non-surgical therapy.

Eligibility criteria:
inclusion criteria: * be aged 18 years old and over * have a minimum of 20 teeth * have chronic periodontitis * be capable of giving informed consent themselves exclusion criteria: * patients with aggressive disease * patients with physical or mental disability * pregnant women or those breastfeeding * patients whose medical history may place them at risk of complications from periodontal therapy (e.g. warfarinised volunteers) * patients taking long term anti-microbial or anti-inflammatory drugs * patients unable to swallow the study capsules, or take 6 of these capsules a day * patients unable to provide informed consent * taking dietary supplements (e.g. multivitamins, antioxidants, fish oils) or have taken them within 1-month of the study * shows unwillingness, inability or lack of motivation to carry out the study procedures or is not prepared to give written consent or to refrain from using other oral hygiene products (mouthwashes, chewing gum, water piks etc.) or to undergo professional dental cleaning for the duration of the study (other than as part of this protocol) * antibiotic or anti-inflammatory therapy currently or in previous two weeks * current orthodontic treatment * currently participating in another dental trial * diabetics

Keywords: periodontitis dietary supplementation